---

Number of phage particles that is adequate to induce replication and therapeutic action at bacterial infections

Range	100 - 1,000 plaque forming units (PFU)
Organism	Bacteriophage
Reference	Rios AC et al., Alternatives to overcoming bacterial resistances: State-of-the-art. Microbiol Res. 2016 Oct191: 51-80. doi: 10.1016/j.micres.2016.04.008 p.57 right column 3rd paragraphPubMed ID27524653
Primary Source	D.D. Rhoads, R.D. Wolcott, M.A. Kuskowski, B.M. Wolcott, L.S. Ward, A. Sulakvelidze, Bacteriophage therapy of venous leg ulcers in humans: results of a phase I safety trial, J. Wound Care, 18 (6) (2009), pp. 237-238 DOI: 10.12968/jowc.2009.18.6.42801 AND A. Wright, C.H. Hawkins, E.E. Anggård, D.R. Harper, A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa a preliminary report of efficacy, Clin. Otolaryngol., 34 (4) (2009), pp. 349-357 doi: 10.1111/j.1749-4486.2009.01973.x AND H.M. Parracho, B.H. Burrowes, M.C. Enright, M.L. McConville, D.R. Harper, The role of regulated clinical trials in the development of bacteriophage therapeutics, J. Mol. Genet. Med., 6 (2012), pp. 279-286PubMed ID19661847, 19673983, 22872803
Comments	P.57 right column 3rd paragraph: "More recent studies indicate that a number of phage particles between 10^2–10^3 plaque forming units (PFU) is adequate to induce replication and therapeutic action at bacterial infections with 10^6–10^9 colony forming units (CFU) per millilitre (primary sources)."
Entered by	Uri M
ID	113977